Medi-Weightloss Company Profile

Background

Overview

Medi-Weightloss is a physician-supervised weight loss program founded in 2005 by Edward Kaloust. The program is designed to help individuals achieve and maintain weight loss through personalized, evidence-based strategies. With over 136 locations across the United States, Medi-Weightloss has assisted more than 400,000 patients in collectively losing over 10 million pounds.

Mission and Vision

The mission of Medi-Weightloss is to combat the obesity epidemic in America by providing scientifically-backed weight loss solutions that lead to sustainable lifestyle changes. The vision is to empower individuals to achieve healthier lives through personalized weight management programs.

Primary Area of Focus

Medi-Weightloss specializes in medically supervised weight loss programs that combine personalized diet plans, fitness recommendations, and, when appropriate, weight loss medications. The program emphasizes long-term weight management and overall health improvement.

Industry Significance

As a leader in the weight loss industry, Medi-Weightloss has set a benchmark for medically supervised weight management programs. Its evidence-based approach and significant patient success stories have contributed to its reputation as a trusted provider in the field.

Key Strategic Focus

Core Objectives

• Personalized Weight Loss Plans: Develop individualized programs tailored to each patient's unique health profile and weight loss goals.

• Sustainable Lifestyle Changes: Promote long-term weight management through education, support, and ongoing monitoring.

• Health Improvement: Address and improve health conditions associated with obesity, such as metabolic syndrome, hypertension, and type 2 diabetes.

Specific Areas of Specialization

• Medically Supervised Programs: Offer weight loss plans overseen by healthcare professionals, including physicians, nurse practitioners, and dietitians.

• Comprehensive Support: Provide weekly check-ins, body composition analysis, medical exams, and nutrition and fitness education.

• Use of FDA-Approved Medications: When appropriate, incorporate FDA-approved weight loss medications into the program to enhance results.

Key Technologies Utilized

• Body Composition Analysis: Utilize advanced tools to assess body fat percentage, muscle mass, and other health metrics.

• Patient Management Systems: Employ electronic health records and scheduling systems to streamline patient care and communication.

Primary Markets or Conditions Targeted

• Obesity and Overweight Individuals: Focus on adults seeking medically supervised weight loss solutions.

• Metabolic Syndrome: Address conditions such as high blood pressure, high blood sugar, and abnormal cholesterol levels.

• Type 2 Diabetes: Assist patients in managing and potentially reversing type 2 diabetes through weight loss and lifestyle changes.

Financials and Funding

Funding History

Medi-Weightloss has undergone significant growth since its inception, expanding its network of clinics and services. In 2025, the company celebrated a milestone of over 10 million pounds lost collectively by its patients, indicating strong financial health and operational success.

Total Funds Raised

Specific details regarding the total funds raised by Medi-Weightloss are not publicly disclosed.

Recent Funding Rounds

In May 2025, Medi-Weightloss was acquired by REP’M Group, a healthcare franchising company. This acquisition is expected to enhance Medi-Weightloss's scalability and reach in the weight loss industry.

Notable Investors

Prior to the acquisition, Medi-Weightloss received investment from Audax Group, a private equity firm.

Intended Utilization of Capital

The capital from the acquisition is likely to be utilized for expanding clinic locations, enhancing program offerings, and investing in technology to improve patient care and operational efficiency.

Pipeline Development

Key Pipeline Candidates

Medi-Weightloss continually evaluates and integrates new weight loss medications and treatments into its programs. The company offers FDA-approved weight loss medications, including phentermine, Wegovy®, Zepbound®, compounded semaglutide, and compounded tirzepatide, as part of its comprehensive program.

Stages of Clinical Trials or Product Development

Medi-Weightloss does not conduct its own clinical trials but incorporates evidence-based treatments and medications that have undergone rigorous clinical testing.

Target Conditions

• Obesity and Overweight Individuals: Focus on weight loss and management.

• Metabolic Syndrome: Address components such as high blood pressure, high blood sugar, and abnormal cholesterol levels.

• Type 2 Diabetes: Assist in managing and potentially reversing type 2 diabetes through weight loss and lifestyle changes.

Relevant Timelines for Anticipated Milestones

Specific timelines for the introduction of new treatments or medications are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Medi-Weightloss utilizes proprietary patient management systems to track progress, schedule appointments, and communicate with patients.

Significant Scientific Methods

• Body Composition Analysis: Employ advanced tools to assess body fat percentage, muscle mass, and other health metrics.

• Evidence-Based Protocols: Implement weight loss strategies supported by clinical research and translational science.

AI-Driven Capabilities

While Medi-Weightloss does not publicly disclose the use of AI-driven technologies, the integration of advanced patient management systems suggests potential utilization of data analytics to enhance patient care and operational efficiency.

Leadership Team

Edward Kaloust – Founder and CEO

Edward Kaloust founded Medi-Weightloss in 2005, aiming to provide effective weight loss solutions. Under his leadership, the company has expanded to over 136 locations nationwide.